文献速递细菌感染、耐药与抗菌药物

中间布鲁氏菌临床多重耐药株中新型氨基糖苷磷酸转移酶APH(3')-IId的鉴定与特征

Identification and characteristics of a novel aminoglycoside phosphotransferase, APH(3')-IId, from an MDR clinical isolate of Brucella intermedia.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

本研究从一名癌症患者的多重耐药中间布鲁氏菌ZJ499临床分离株中鉴定出一种新型染色体氨基糖苷磷酸转移酶APH(3')-IId。通过基因克隆、转录分析、基因缺失和蛋白纯化动力学分析,发现该酶由266个氨基酸组成,与已知APH(3')-IIb同源性最高(48.25%),其表达可降低大肠杆菌对卡那霉素、新霉素、巴龙霉素和核糖霉素的敏感性,纯化蛋白对这四种药物具有磷酸转移酶活性(kcat/Km约10^5至10^7 M^-1 s^-1)。该基因缺失可降低ZJ499对上述药物的MIC,且其周围未检测到移动遗传元件,提示可能为布鲁氏菌属普遍存在的染色体基因。

要点

  • APH(3')-IId是第四个被鉴定的APH(3')-II酶,由266个氨基酸组成。
  • 该酶介导卡那霉素、新霉素、巴龙霉素和核糖霉素耐药。
  • 基因位于染色体,周围无移动遗传元件,可能为布鲁氏菌属固有基因。

核心结论

  • APH(3')-IId是一种新型染色体氨基糖苷磷酸转移酶,在中间布鲁氏菌ZJ499对卡那霉素、新霉素、巴龙霉素和核糖霉素的耐药中起重要作用。

研究设计与样本

  • 研究对来自癌症患者的多重耐药中间布鲁氏菌ZJ499分离株进行PCR和MALDI-TOF MS菌种鉴定及全基因组测序。
  • 通过基因克隆、转录分析、靶向基因缺失、蛋白纯化及动力学分析探究耐药机制。

主要发现

  • APH(3')-IId由266个氨基酸组成,与已知APH(3')-IIb同源性最高(48.25%)。
  • 在大肠杆菌中表达aph(3')-IId降低了对卡那霉素、新霉素、巴龙霉素和核糖霉素的敏感性。
  • ZJ499中aph(3')-IId基因在实验室条件下有转录活性,且上述四种抗生素处理不影响其转录本相对丰度。
  • 敲除aph(3')-IId导致ZJ499对上述药物的MIC降低。
  • 纯化的APH(3')-IId对卡那霉素、新霉素、巴龙霉素和核糖霉素具有磷酸转移酶活性,催化效率(kcat/Km)约为10^5至10^7 M^-1 s^-1。

关键数值与推荐

  • APH(3')-IId与APH(3')-IIb氨基酸同源性为48.25%。
  • APH(3')-IId对卡那霉素、新霉素、巴龙霉素和核糖霉素的kcat/Km约为10^5至10^7 M^-1 s^-1。

临床怎么用

  • 临床分离中间布鲁氏菌时,应关注aph(3')-IId基因介导的氨基糖苷类耐药,尤其对卡那霉素、新霉素、巴龙霉素和核糖霉素。

局限性

  • 研究仅基于一株临床分离株ZJ499,APH(3')-IId在布鲁氏菌属中的流行性和临床影响需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe a novel chromosomal aminoglycoside phosphotransferase named APH(3')-IId identified in an MDR Brucella intermedia ZJ499 isolate from a cancer patient. METHODS: Species identity was determined by PCR and MALDI-TOF MS analysis. WGS was performed to determine the genetic elements conferring antimicrobial resistance. Gene cloning, transcriptional analysis and targeted gene deletion, as well as protein purification and kinetic analysis, were performed to investigate the mechanism of resistance. RESULTS: APH(3')-IId consists of 266 amino acids and shares the highest identity (48.25%) with the previously known APH(3')-IIb. Expression of aph(3')-IId in Escherichia coli decreased susceptibility to kanamycin, neomycin, paromomycin and ribostamycin. The aph(3')-IId gene in ZJ499 was transcriptionally active under laboratory conditions and the relative abundance of this transcript was unaffected by treatment with the above four antibiotics. However, deletion of aph(3')-IId in ZJ499 results in decreased MICs of these drugs. The purified APH(3')-IId showed phosphotransferase activity against kanamycin, neomycin, paromomycin and ribostamycin, with catalytic efficiencies (kcat/Km) ranging from ∼105 to 107 M-1 s-1. Genetic environment and comparative genomic analyses suggested that aph(3')-IId is probably a ubiquitous gene in Brucella, with no mobile genetic elements detected in its surrounding region. CONCLUSIONS: APH(3')-IId is a novel chromosomal aminoglycoside phosphotransferase and plays an important role in the resistance of B. intermedia ZJ499 to kanamycin, neomycin, paromomycin and ribostamycin. To the best of our knowledge, APH(3')-IId represents the fourth characterized example of an APH(3')-II enzyme.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Lu W, Li K, Huang J, et al. Identification and characteristics of a novel aminoglycoside phosphotransferase, APH(3')-IId, from an MDR clinical isolate of Brucella intermedia. J Antimicrob Chemother. 2021. PMID: 34329431. doi:10.1093/jac/dkab272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。